Levosimendan

This classification denotes an anti-arrhythmia agent, cardiotonic agent, and vasodilator agent with the molecular formula C14H12N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C6T4514L4E, chemically known as (r)-((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile but generally known as levosimendan, which bears US NIH Compound Identifier 3033825. European Medicines Agency schedules Levosimendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08493MIG. World Health Organization schedules levosimendan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule levosimendan under HS 29339990 and SITC 51577. As of Q4 2014, LEVOSIMENDAN remains the US FDA Preferred Term for this commodity. SMILES: O=C1NN=C(C(C1)C)c1ccc(N/N=C(/C#N)C#N)cc1.